PT Kedoya Adyaraya Tbk (RSGK.JK)
IDR 990.0
(-1.0%)
IDR 990.0
(-1.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 373.39 Billion IDR | 3.97% |
| 2022 | 359.15 Billion IDR | -17.47% |
| 2021 | 435.19 Billion IDR | 47.57% |
| 2020 | 294.91 Billion IDR | 3.59% |
| 2019 | 284.7 Billion IDR | 17.17% |
| 2018 | 242.98 Billion IDR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 117.51 Billion IDR | 18.26% |
| 2024 Q3 | 109.65 Billion IDR | 2.18% |
| 2024 Q2 | 107.31 Billion IDR | -8.68% |
| 2023 Q2 | 87.62 Billion IDR | -4.22% |
| 2023 Q1 | 91.48 Billion IDR | -2.67% |
| 2023 FY | 373.39 Billion IDR | 3.97% |
| 2023 Q4 | 99.36 Billion IDR | 4.68% |
| 2023 Q3 | 94.92 Billion IDR | 8.34% |
| 2022 Q3 | 99.15 Billion IDR | 30.71% |
| 2022 Q2 | 75.85 Billion IDR | -15.86% |
| 2022 FY | 359.15 Billion IDR | -17.47% |
| 2022 Q1 | 90.15 Billion IDR | 0.64% |
| 2022 Q4 | 93.98 Billion IDR | -5.21% |
| 2021 Q1 | 119.62 Billion IDR | 22.65% |
| 2021 FY | 435.19 Billion IDR | 47.57% |
| 2021 Q4 | 89.58 Billion IDR | -19.61% |
| 2021 Q3 | 111.43 Billion IDR | -2.72% |
| 2021 Q2 | 114.55 Billion IDR | -4.24% |
| 2020 Q4 | 97.52 Billion IDR | 0.0% |
| 2020 FY | 294.91 Billion IDR | 3.59% |
| 2019 FY | 284.7 Billion IDR | 17.17% |
| 2018 FY | 242.98 Billion IDR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| PT Bundamedik Tbk | 1488.19 Billion IDR | 74.909% |
| PT Metro Healthcare Indonesia Tbk | 242.68 Billion IDR | -53.865% |
| PT Medikaloka Hermina Tbk | 5784.08 Billion IDR | 93.544% |
| PT Mitra Keluarga Karyasehat Tbk | 4264.27 Billion IDR | 91.244% |
| PT Murni Sadar Tbk | 921.91 Billion IDR | 59.497% |
| PT Famon Awal Bros Sedaya Tbk | 1839.23 Billion IDR | 79.698% |
| PT Royal Prima Tbk | 265.33 Billion IDR | -40.727% |
| PT Sarana Meditama Metropolitan Tbk | 1535.63 Billion IDR | 75.684% |
| PT Siloam International Hospitals Tbk | 11190.51 Billion IDR | 96.663% |
| PT Sejahteraraya Anugrahjaya Tbk | 2503.17 Billion IDR | 85.083% |